Nasal Polyps Pipeline Insight 2025: Unveiling the Future of Chronic Rhinosinusitis Therapy with 4+ Targeted Candidates | DelveInsight

DelveInsight's "Nasal Polyps - Pipeline Insight, 2025" report offers a detailed overview of the evolving pipeline landscape for nasal polyps, particularly chronic rhinosinusitis with nasal polyps (CRSwNP). The report analyzes more than 4 investigational therapies in various stages of clinical development, with a focus on biologics that target type 2 inflammation and related immune pathways.

Recent advances are shifting treatment strategies away from systemic corticosteroids and repeated surgeries toward precision biologics targeting interleukins such as IL-4, IL-5, IL-13, and IgE. Candidates include Benralizumab, CM-310, and Tezepelumab, all demonstrating significant efficacy in reducing nasal polyp burden and improving patient quality of life.

Emerging pipeline assets aim to optimize delivery routes (intranasal or subcutaneous), improve durability of response, and reduce recurrence. Companies like GlaxoSmithKline, Genentech, Allakos, and others are advancing novel monoclonal antibodies and small molecules targeting key inflammatory mediators in CRSwNP pathogenesis.

The report offers a comprehensive review of each drug's mechanism of action, stage of development, clinical trial status, and regulatory progress. It also highlights key unmet needs, evolving biomarkers, and innovation opportunities that could influence future treatment paradigms.

With a growing pipeline of biologic therapies, the nasal polyps space is transforming, providing hope for long-term, non-surgical management of this chronic, recurrent condition.

Interested in learning more about the current treatment landscape and the key drivers shaping the Nasal Polyps pipeline? Click here: https://www.delveinsight.com/report-store/nasal-polyps-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Nasal Polyps Pipeline Report
• DelveInsight's nasal polyps pipeline analysis depicts a strong space with 4+ active players working to develop 4+ pipeline drugs for nasal polyps treatment.
• The leading nasal polyps companies include Biohaven Pharmaceuticals, KeyMed Biosciences, AstraZeneca, Amgen, Connect Biopharma, GlaxoSmithKline, and others are evaluating their lead assets to improve the nasal polyps treatment landscape.
• Key nasal polyps pipeline therapies in various stages of development include Benralizumab, CM-310, Tezepelumab, and others.
• In March 2025, GSK announced that the FDA accepted its Biologics License Application for depemokimab. The drug is proposed as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation, and for adults with chronic rhinosinusitis with nasal polyps (CRSwNP) not adequately controlled by existing therapies.
• In January 2025, GSK's IL-5 inhibitor Nucala was approved in China for the treatment of individuals with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting nearly 30 million people in the country.
• In November 2024, AstraZeneca and Amgen announced that their subcutaneous antibody TEZSPIRE (tezepelumab) met the primary endpoint in the Phase III WAYPOINT study, showing significant efficacy in patients with chronic rhinosinusitis with nasal polyps.

Request a sample and discover the recent breakthroughs happening in the nasal polyps pipeline landscape at https://www.delveinsight.com/report-store/nasal-polyps-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Nasal Polyps Overview
Nasal polyps are non-cancerous, soft, painless growths that develop on the lining of the nasal passages or sinuses due to chronic inflammation. They are often associated with conditions like chronic rhinosinusitis, asthma, allergies, and aspirin sensitivity. When they become large or numerous, they can block nasal passages and lead to breathing difficulties, frequent infections, reduced sense of smell, and nasal congestion.

Though nasal polyps can affect anyone, they are more common in adults and tend to recur even after treatment. Current management options include corticosteroid sprays, oral steroids, and, in severe cases, surgery. However, recent advances in biologics are transforming treatment by targeting the underlying inflammation rather than just relieving symptoms.

With increasing research and clinical activity, the landscape for nasal polyp treatment is rapidly evolving, moving toward personalized therapies aimed at long-term disease control and improved quality of life.

Find out more about nasal polyps medication at https://www.delveinsight.com/report-store/nasal-polyps-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Nasal Polyps Treatment Analysis: Drug Profile
Tezepelumab: AstraZeneca
Tezepelumab, developed by AstraZeneca in collaboration with Amgen, is a potential first-in-class human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP)-a key cytokine involved in triggering and sustaining airway inflammation in severe asthma. TSLP is released in response to asthma triggers such as allergens, viruses, and airborne particles, and its levels are elevated in patients with more severe disease. By blocking TSLP, tezepelumab may help prevent the release of pro-inflammatory cytokines, reducing asthma exacerbations and improving disease control. Unlike many current treatments, it has the potential to benefit a broad range of severe asthma patients, regardless of biomarker levels. Tezepelumab is currently in Phase III development for chronic rhinosinusitis with nasal polyps (CRSwNP).

Learn more about the novel and emerging nasal polyps pipeline therapies at https://www.delveinsight.com/report-store/nasal-polyps-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Nasal Polyps Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Nasal Polyps Pipeline Report
• Coverage: Global
• Key Nasal Polyps Companies: Biohaven Pharmaceuticals, KeyMed Biosciences, AstraZeneca, Amgen, Connect Biopharma, GlaxoSmithKline, and others.
• Key Nasal Polyps Pipeline Therapies: CM-310, Tezepelumab, Benralizumab, and others.

To dive deep into rich insights for drugs used for nasal polyps treatment, visit: https://www.delveinsight.com/report-store/nasal-polyps-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Nasal Polyps Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Nasal Polyps Pipeline Therapeutics
6. Nasal Polyps Pipeline: Late-Stage Products (Phase III)
7. Nasal Polyps Pipeline: Mid-Stage Products (Phase II)
8. Nasal Polyps Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.